Transfusion-related Cost Offsets and Time Burden in Patients with Myelofibrosis on Momelotinib Vs. Danazol from MOMENTUM.
FUTURE ONCOLOGY(2024)
Key words
ACVR1,anemia,cost,danazol,JAK inhibitor,momelotinib,myelofibrosis,time burden,transfusion
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined